Study wrapper · #890
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
Aroda VR, Buzzetti R, Dalskov SM, et al. The lancet. Diabetes & endocrinology. 2026.
DOI: 10.1016/s2213-8587(26)00126-9PubMed: 42251860
Editor's note
This placebo-controlled phase 3a RCT tested cagrilintide-semaglutide in early type 2 diabetes, showing large HbA1c and weight reductions versus placebo. Semaglutide is a core component, though effects reflect the combination rather than semaglutide alone. The trial was Novo Nordisk-funded and placebo-controlled rather than compared to semaglutide monotherapy, so the isolated semaglutide contribution is not separable here.
Plain-language abstract
In this phase 3a trial, the cagrilintide-semaglutide combination lowered HbA1c by up to 1.8 points and reduced body weight by about 14% versus placebo in adults with early type 2 diabetes.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026